Sangamo Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sangamo Therapeutics Inc (SGMO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sangamo Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 35M vs 11,512M combined for tracked competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-83.3% annualized vs trailing 12 months), vs decelerating (-16.2%) for its tracked peer group.
- Growth: Sangamo Therapeutics Inc generated -77.6% revenue growth year over year in Q1 2026, vs 44.6% for its tracked competitors combined.
- Profitability: Its -2,149.5% net margin compares with -129.1% for the peer group.
- Peer revenue share: Sangamo Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.24M compares with $0.60M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SGMO Sales vs. its Competitors, Q1 2026
Sangamo Therapeutics Inc reported revenue contraction of 77.60 % year on year in Q1 2026, below its competitors' combined revenue growth of 44.62 %.
With a net margin of -2,149.45 %, Sangamo Therapeutics Inc reported lower profitability than its competitors (-129.07 %).
Sangamo Therapeutics Inc generated 0.06 % of the combined sales of its peer group, down from 0.38 % a year earlier.
Sangamo Therapeutics Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Sangamo Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Sangamo Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Sangamo Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Sangamo Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.1% year over year, combined, vs -77.6% for Sangamo Therapeutics Inc. Sangamo Therapeutics Inc's share of combined industry revenue moved from 0.02% to 0.00%, a loss of 0.01 percentage points.
Sangamo Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sangamo Therapeutics Inc | - | No | No | Yes |
| Competitors combined (59) | ||||
| High-Confidence Competitors (9) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SGMO Stock Performance relative to its Competitors
SGMO Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Kodiak Sciences Inc | 282.9% | Outperformed |
| 3 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 4 | Century Therapeutics inc | 282.9% | Outperformed |
| 5 | Relay Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sangamo Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sangamo Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Sangamo Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Sangamo Therapeutics Inc | 28.83 | 34.56 |
| Moderna Inc | 93,846.41 | 2,228.00 |
| Alnylam Pharmaceuticals Inc | 31,151.94 | 4,804.18 |
| Krystal Biotech Inc | 10,047.22 | 440.48 |
| Ionis Pharmaceuticals Inc | 7,404.15 | 1,169.42 |
| Kodiak Sciences Inc | 5,499.42 | - |
| SUBTOTAL | 184,780.76 | 11,741.33 |
Sign in to see all competitors of Sangamo Therapeutics Inc .
Sources: Sangamo Therapeutics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sangamo Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sangamo Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Sangamo Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Voyager Therapeutics Inc | Company report | 85% |
| Jupiter Neurosciences Inc | Company report | 85% |
| Tc Biopharm holdings Plc | Company report | 85% |
| Cue Biopharma Inc | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Q32 Bio Inc | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| RENB | Company report | 85% |
| Caribou Biosciences Inc | Company report | 85% |
| Celularity Inc | Company report | 85% |
| Editas Medicine Inc | Company report | 85% |
| Alnylam Pharmaceuticals Inc | Company report | 85% |
| Wave Life Sciences Ltd | Company report | 85% |
| Prime Medicine Inc | Company report | 85% |
| Ionis Pharmaceuticals Inc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Regulus Therapeutics Inc | Company report | 85% |
| Orchard Therapeutics Plc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Crispr Therapeutics Ag | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Taysha Gene Therapies Inc | Company report | 85% |
| Passage Bio Inc | Company report | 85% |
| Precision Biosciences Inc | Company report | 85% |
| Ultragenyx Pharmaceutical Inc | Company report | 85% |
| Verve Therapeutics Inc | Company report | 85% |
| Poseida Therapeutics Inc | Company report | 85% |
| Abeona Therapeutics Inc | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Meiragtx Holdings Plc | Company report | 85% |
| Century Therapeutics inc | Company report | 85% |
| Sigilon Therapeutics Inc | Company report | 85% |
| Beam Therapeutics Inc | Company report | 85% |
| Applied Genetic Technologies Corporation | Company report | 85% |
| 4d Molecular Therapeutics Inc | Company report | 85% |
| Precigen Inc | Company report | 85% |
| Lexeo Therapeutics Inc | Company report | 85% |
| Vor Biopharma Inc | Company report | 85% |
| Bluebird Bio Inc | Company report | 85% |
| Generation Bio Co | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sangamo Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Sangamo Therapeutics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Sangamo Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Sangamo Therapeutics Inc | Reportable 100.00 % |
| Ionis Pharmaceuticals Inc | Ionis Operations 100.00 % |
| Precigen Inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Uniqure N v | Single Reportable Segment 100.00 % |
| Prime Medicine Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Sangamo Therapeutics Inc .
Sangamo Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sangamo Therapeutics Inc | 29 | 243,359 | -868,521 |
| Moderna Inc | 93,846 | 474,043 | -670,426 |
| Alnylam Pharmaceuticals Inc | 31,152 | 1,921,673 | 323,195 |
| Krystal Biotech Inc | 10,047 | 1,493,166 | 818,525 |
| Ionis Pharmaceuticals Inc | 7,404 | 834,108 | -223,265 |
| Kodiak Sciences Inc | 5,499 | - | -1,951,565 |
| PEERS TOTAL | 184,752 | 601,767 | -433,352 |
Sign in to see all peers for Sangamo Therapeutics Inc .
Sangamo Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Krystal Biotech Inc | United States 75.19 % |
| Ultragenyx Pharmaceutical Inc | North America 43.38 % |
| 4d Molecular Therapeutics Inc | JP 97.05 % |
| Maxcyte inc | US 68.55 % |
| Caribou Biosciences Inc | United States 94.16 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sangamo Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Sangamo Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Sangamo Therapeutics Inc ranks #0 of 159 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,319, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 240,968 | 26.05 % |
| 2 | Gilead Sciences Inc | 192,379 | 20.80 % |
| 3 | Moderna Inc | 93,846 | 10.15 % |
| 4 | Argenx Se | 58,494 | 6.32 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 0 | Sangamo Therapeutics Inc | 29 | 0.00 % |
Market cap and industry share for the rest of Sangamo Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-07-02.
Sangamo Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 39.10 % (avg) | -39.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.50 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.33 % | 9.14 % (avg) | -8.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Sangamo Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 22.7x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | -84.0x | 5.0x | -89.0x |
| Return on Equity | 6,686.36 % | industry aggregate | 6,672.86 % |
| Return on Invested Capital | -470.03 % | -5.14 % (avg) | -464.89 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sangamo Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 97.94 % | 21.29 % | 15.39 % | -6.34 % | 0.54 % | 58.34 % | -67.20 % | -31.57 % |
| Operating Margin | -91.35 % | -102.69 % | -109.61 % | -165.61 % | -180.85 % | - | - | - |
| Return on Invested Capital | -9.81 % | -11.07 % | -10.62 % | -16.77 % | -25.06 % | -63.36 % | -101.69 % | -305.42 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sangamo Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,319 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.33 % vs industry average 9.14 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Sangamo Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Sangamo Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Sangamo Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 6,672.9 points above the industry aggregate.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-83.3% annualized vs trailing 12 months).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (48.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-16.2% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Sangamo Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sangamo Therapeutics Inc | 0.60 | 0.86 | - |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Alnylam Pharmaceuticals Inc | 1.12 | 2.86 | 1.18 |
| Krystal Biotech Inc | 5.21 | 9.38 | - |
| Ionis Pharmaceuticals Inc | 0.44 | 4.06 | 1.98 |
| Kodiak Sciences Inc | 3.03 | 3.14 | - |
Sign in to see all peers for Sangamo Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sangamo Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sangamo Therapeutics Inc | Q1 2026 | -77.6 % | - |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +66.9 % | - |
| Krystal Biotech Inc | Q2 2026 | +24.1 % | +42.9 % |
| Ionis Pharmaceuticals Inc | Q2 2026 | +103.6 % | - |
| Kodiak Sciences Inc | Q2 2026 | - | - |
| PEERS TOTAL | +73.8 % | - |
Sign in to see all peers for Sangamo Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sangamo Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sangamo Therapeutics Inc | Q1 2026 | - | - |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +110.0 % | +142.6 % |
| Krystal Biotech Inc | Q2 2026 | - | +87.2 % |
| Ionis Pharmaceuticals Inc | Q2 2026 | +87.2 % | +37.8 % |
| Kodiak Sciences Inc | Q2 2026 | - | +164.7 % |
Sign in to see all peers for Sangamo Therapeutics Inc .
Sangamo Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sangamo Therapeutics Inc | - | - | - |
| Moderna Inc | - | - | - |
| Alnylam Pharmaceuticals Inc | 15.76% | 22.10% | 93.61% |
| Krystal Biotech Inc | 17.65% | 19.16% | 19.34% |
| Ionis Pharmaceuticals Inc | - | - | - |
| Kodiak Sciences Inc | - | - | - |
Sign in to see all peers for Sangamo Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sangamo Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sangamo Therapeutics Inc | - | 0.83 |
| Moderna Inc | - | 42.12 |
| Alnylam Pharmaceuticals Inc | 39.87 | 6.48 |
| Krystal Biotech Inc | 40.97 | 22.81 |
| Ionis Pharmaceuticals Inc | - | 6.33 |
| Kodiak Sciences Inc | - | - |
| PEERS AVERAGE | - | 15.74 |
Sign in to see all peers for Sangamo Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.